Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.
1 . A method of administering a once-daily dose of deutetrabenazine in an osmotic dosage form for treating a hyperkinetic movement disorder in a subject in need thereof comprising:
orally administering to the subject, on a once daily basis, the osmotic dosage form, wherein the dosage form comprises
a. a tablet core comprising an active layer and a push layer, wherein the active layer comprises an amount of deutetrabenazine microparticles and an active layer control release agent, and wherein the push layer comprises an osmotic agent and a push layer control release agent, and an optional tablet seal coat on the outer surface of the tablet core;
b. a semipermeable layer surrounding the tablet core;
c. a port extending through the semipermeable layer into the tablet core; and
d. an immediate release coating external to the semipermeable layer comprising a second amount of deutetrabenazine microparticles,
wherein the dosage comprises from about 6 mg to about 48 mg deutetrabenazine in the form of deutetrabenzine microparticles and wherein about 70%-80% of the total amount of deutetrabenazine microparticles present in the dosage form is present within the active layer and wherein about 20%-30% of the total amount of deutetrabenazine microparticles present in the dosage form, is present within the immediate release coating; and
wherein the deutetrabenazine microparticles have a D 90 of 15 μm, a D 50 10 μm, and/or a D 10 of 3 μm.
2 . The method according to claim 1 , wherein the movement disorder is chorea, akathisia, dyskinesia, tremor, tic, chorea associated with Huntington's disease, tardive dyskinesia, a tic associated with Tourette syndrome, Parkinson's disease levodopa-induced dyskinesia or dyskinesia in cerebral palsy.
3 . The method according to claim 1 , wherein the dosage form comprises a total amount of 6 mg of deutetrabenazine microparticles.
4 . The method of claim 1 , wherein the dosage form comprises a total amount of 12 mg of deutetrabenazine microparticles.
5 . The method of claim 1 , wherein the dosage form comprises a total amount of 24 mg of deutetrabenazine microparticles.
6 . The method of claim 1 , wherein the dosage form comprises a total amount of 36 mg of deutetrabenazine microparticles.
7 . The method of claim 1 , wherein the dosage form comprises a total amount of 48 mg of deutetrabenazine microparticles.
8 . The method of claim 1 , wherein not more than 15% of a drug formulation comprising the amount of the deutetrabenazine is released after 2 hours when tested in 500 mL acid phosphate buffer at pH 3.0 using a USP II dissolution apparatus; or not more than 60% of the drug formulation is released after 8 hours when tested in 500 mL acid phosphate buffer at pH 3.0 using a USP II dissolution apparatus.
9 . The method of claim 1 , wherein the active layer control release agent comprises a polymer having a viscosity of about 50-150 mPa s or about 55-90 mPa S.
10 . The method of claim 9 , wherein the active layer control release agent polymer comprises a polyethylene oxide having an average molecular weight of 100,000 Daltons to 500,000 Daltons in an amount of about 60% to about 98% by weight, based on the total weight of the active layer.
11 . The method of claim 1 , wherein the active layer further comprises at least one of:
a. an active layer antioxidant present in an amount of about 0.001% to about 1% by weight, based on the total weight of the active layer; and
b. an active layer binder present in an amount of about 2% to about 20% by weight, based on the total weight of the active layer.
12 . The method of claim 1 , wherein the osmotic agent comprises an inorganic salt, a carbohydrate or any mixture thereof.
13 . The method of claim 12 , wherein the osmotic agent comprises an inorganic salt selected from magnesium sulfate, magnesium chloride, potassium sulfate, sodium chloride, sodium sulfate, lithium sulfate, sodium phosphate, potassium phosphate or any mixture thereof and is present in an amount of about 5% to about 50% by weight, based on the total weight of the dosage form.
14 . The method of claim 1 , wherein the push layer control release agent comprises a polymer having a viscosity of about 5500-7500 mPa s and is present in an amount of about 50% to about 80% by weight, based on the total weight of the push layer.
15 . The method of claim 1 , wherein the weight ratio of the osmotic agent and the push layer control release agent in the push layer is 1:2-1:3.5 or 1:2-1:2.5.
16 . The method of claim 1 , wherein the push layer further comprises at least one of:
a. a push layer binder; and
b. a pharmaceutically acceptable excipient.
17 . The method of claim 1 , wherein the semipermeable layer comprises a water soluble polymer, a water insoluble polymer or any mixture thereof.
18 . The method of claim 17 , wherein the semipermeable layer comprises a water insoluble polymer selected from cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose propionate, cellulose acetate butyrate, cellulose ethers like ethyl cellulose, agar acetate, amylose triacetate, betaglucan acetate, poly(vinyl methyl) ether copolymers, poly(orthoesters), poly acetals and selectively permeable poly(glycolic acid), poly(lactic acid) derivatives, cellulose acetate polymer or any mixture thereof in an amount of about 80% to about 99.9% by weight, based on the weight of the semipermeable layer.
19 . The method of claim 1 , wherein the semipermeable layer comprises a pore-forming agent.
20 . The method of claim 19 , wherein the pore-forming agent comprises a water soluble sugar, a water soluble salt, a water soluble solvent, a water soluble polymer or any mixture thereof and is present in the semipermeable layer in an amount of about 0.1% to about 20% by weight of the semipermeable layer.
21 . The method of claim 1 , wherein the weight ratio of the semipermeable layer and the tablet core is 1:8-1:10.
22 . The method of claim 1 , wherein the port has a diameter of from about 0.1 mm to about 1 mm.
23 . The method of claim 1 , further comprising a semipermeable layer seal coat on the outer surface of the semipermeable layer.
24 . The method of claim 23 , wherein each of the tablet core seal coat and the semipermeable layer seal coat independently comprise a binder in an amount up to about 20% by weight, based on the total weight of the dosage form.
25 . The method of claim 1 , comprising the immediate release coating external to the semipermeable membrane, the immediate release coating comprising about 0.1% to about 30% by weight deutetrabenazine microparticles, based on the total weight of the dosage form or about 0.2% to about 5% by weight deutetrabenazine microparticles, based on the total weight of the dosage form or about 0.3% to about 2% by weight deutetrabenazine microparticles, based on the total weight of the dosage form.
26 . The method of claim 25 , wherein the dosage form comprises:
a. a total amount of 6 mg of deutetrabenazine microparticles wherein the immediate release coating comprises about 0.1% to about 0.5% by weight deutetrabenazine microparticles, based on the total weight of the dosage form, or
b. a total amount of 12 mg of deutetrabenazine microparticles wherein the immediate release coating comprises about 0.5% to about 1% by weight deutetrabenazine microparticles, based on the total weight of the dosage form, or
c. a total amount of 24 mg of deutetrabenazine microparticles wherein the immediate release coating comprises about 1% to about 2% by weight deutetrabenazine microparticles, based on the total weight of the dosage form.
27 . The method of claim 1 , comprising:
a) a total amount of 6 mg of deutetrabenazine microparticles, wherein the total amount of deutetrabenazine microparticles is about 0.5% to about 3% by weight, based on the total weight of the dosage form, or
b) a total amount of 12 mg of deutetrabenazine microparticles, wherein the total amount of deutetrabenazine microparticles is about 1% to about 5% by weight, based on the total weight of the dosage form, or
c) a total amount of 24 mg of deutetrabenazine microparticles, wherein the total amount of deutetrabenazine microparticles is about 5% to about 10% by weight, based on the total weight of the dosage form.
28 . A method of administering a once-daily dose of deutetrabenazine in an osmotic dosage form for treating a hyperkinetic movement disorder in a subject in need thereof comprising:
orally administering to the subject, on a once daily basis, the osmotic dosage form, wherein the dosage form comprises,
a. a tablet core comprising an active layer and a push layer, wherein the active layer comprises an amount of deutetrabenazine microparticles and an active layer control release agent, and wherein the push layer comprises an osmotic agent and a push layer control release agent, and an optional tablet seal coat on the outer surface of the tablet core;
b. a semipermeable layer surrounding the tablet core;
c. a port extending through the semipermeable layer into the tablet core; and
d. an immediate release coating external to the semipermeable layer comprising a second amount of deutetrabenazine microparticles,
wherein the dosage comprises from about 6 mg to about 48 mg deutetrabenazine in the form of deutetrabenzine microparticles and wherein about 70%-80% of the total amount of deutetrabenazine microparticles present in the dosage form is present within the active layer and wherein about 20%-30% of the total amount of deutetrabenazine microparticles present in the dosage form, is present within the immediate release coating;
wherein the deutetrabenazine microparticles have a D 90 of 15 μm, a D 50 10 μm, and/or a D 10 of 3 μm, and
wherein the subject is in a fasted state at the time of the oral administration.
29 . The method according to claim 28 , wherein prior to the administration, the subject had fasted overnight for at least 10 hours.
30 . The method according to claim 28 , wherein the dosage form provides bioavailability of deutetrabenazine and bioavailability of deuHTBZ in the subject that is independent of any food effect.
31 . The method according to claim 1 , wherein the administration is without food.